

WYETH  
Form 425  
April 07, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): April 7, 2009

**PFIZER INC.**

(Exact name of registrant as specified in its charter)

|   |  |  |
|---|--|--|
| <b>Delaware</b><br>(State or other Jurisdiction of<br>incorporation)                                    | <b>1-3619</b><br>(Commission File<br>Number) | <b>13-5315170</b><br>(I.R.S. Employer Identification<br>No.) |
| <b>235 East 42nd Street</b><br><b>New York, New York</b><br>(Address of principal<br>executive offices) |  | <b>10017</b><br>(Zip Code)                                   |

Registrant's telephone number, including area code:  
(212) 573-2323

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On April 7, 2009, Pfizer Inc. issued a press release announcing the operating structure of the Company and certain senior leadership positions that will be effective upon the closing of its acquisition of Wyeth. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. On April 7, 2009, Pfizer also distributed a letter from Pfizer Chairman and CEO, Jeffrey B. Kindler, to Pfizer's employees. A copy of the letter to employees is attached hereto as Exhibit 99.2 and is incorporated by reference herein..

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

- |      |   |
|------|---|
| 99.1 | Pfizer Inc. Press Release dated April 7, 2009 |
| 99.2 | Letter to Pfizer Employees                    |

**SIGNATURE**

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Matthew Lepore  
Matthew Lepore

Title: Vice President, Chief Counsel - Corporate  
Governance, and Assistant General Counsel

Dated: April 7, 2009

**EXHIBIT INDEX**

- | <b>Exhibit No.</b> | <b>Description</b>                            |
|--------------------|---|
| 99.1               | Pfizer Inc. Press Release dated April 7, 2009 |
| 99.2               | Letter to Pfizer Employees                    |